Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 25

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Study on Atypical Teratoid/Rhabdoid Tumors in Children Using Dactinomycin, Carboplatin, and Cyclophosphamide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Neoplasm

Recruiting

Study on the Safety and Effectiveness of IMA402, Tocilizumab, and Human Serum Albumin for Patients with Recurrent or Resistant Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Immatics Biotechnologies GmbH

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Immunocore Limited

Breast cancer

Recruiting

Study on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:GBG Forschungs GmbH

Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Universitair Medisch Centrum Utrecht

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Universitaetsmedizin Goettingen

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Study on Oral Propranolol for Preventing Severe Retinopathy in Premature Infants

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Propranolol Hydrochloride
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.